Partnered product candidates
In May 2019, bluebird bio announced that it intends to start clinical development in 2020 of the first therapeutic TCR candidate arising from the collaboration. bluebird bio presented preclinical data on the TCR candidate targeting the tumor antigen MAGE-A4, which is expressed by a variety of solid tumor types.
Medigene has granted Roivant/Cytovant in April 2019 an exclusive license to develop, manufacture and commercialize a TCR targeting NY-ESO-1 that is currently in the research stage, as well as a DC vaccine targeting the antigens Wilm’s Tumor 1 (WT‑1) and PRAME, in the regions of Greater China, South Korea and Japan
In 2016, Medigene entered into a collaboration with Max-Delbrück-Centrum für Molekulare Medizin MDC and The Charité - University Clinic (“Charité”) to conduct an investigator-initiated clinical trial for a TCR-T cell therapy targeting the antigen MAGE-A1 in multiple myeloma (MM)